About Us

Our Mission

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, botulism, Ebola, anthrax and opioid overdose emergencies. We help prepare communities for today’s health challenges and tomorrow’s threats by:

  • Empowering the public with the resources to respond to an opioid overdose emergency
  • Delivering medical countermeasures to fight critical, even deadly, biological threats
  • Stepping up to help address emerging and infectious diseases

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Our History

A red brick building features a large "EMERGENT" sign in white letters, with the last "N" in red. The bold lettering highlights the emergent brand, while green leaves from a nearby tree frame the left side of the image.
1998

Emergent opened for business, partnering with the U.S. government to supply BioThrax (Anthrax Vaccine Absorbed) for military members.

2001

Terror attacks and subsequent anthrax letter incidents call for increased production of BioThrax, the only FDA-licensed anthrax vaccine at the time.

Began development of CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted), previously known as AV7909.

2002
2003

Acquired first Maryland-based site in Gaithersburg.

A blurred image of people walking in a modern office hallway, with a large black "EMERGENT" sign on a wooden wall and an emergent decorative pattern on the glass door in the background.
2006

Emergent BioSolutions common stock begins trading on the New York Stock Exchange ($EBS).

2007

Received first multi-year contract for BioThrax (Anthrax Vaccine Absorbed) by the U.S. government.

A scientist in protective gear, including a lab coat, gloves, face mask, hair cover, and safety goggles, examines an emergent sample vial in a laboratory setting behind a clear protective barrier.
2008

Received funding for CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted) from the Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID).

2009

Acquired a manufacturing facility in Baltimore’s Bayview neighborhood.

Initiated Phase 1 study for CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted).

2010
2014

Acquired Cangene Corporation, a Canadian company based in Winnipeg, which has since become one of Emergent’s largest manufacturing sites.

A scientist in a white lab coat and safety glasses uses a pipette at a laboratory workstation with blue cabinets, various lab equipment, and emergent research technologies.
2015

Acquired rights to auto-injector technology, growing our devices business.

2017

Acquired ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) and raxibacumab (a fully human monoclonal antibody).

A gloved hand holds an emergent Narcan (naloxone) 4 mg nasal spray, used for the emergency treatment of opioid overdoses. The clear packaging reveals the white and red nasal spray device inside.
2018

Acquired NARCAN® Nasal Spray (naloxone HCl).

2022

Acquired TEMBEXA® (brincidofovir) and announced collaboration with Ridgeback Therapeutics to expand availability of EbangaTM (Ansuvimab-zykl).

Received approval for over-the-counter designation for NARCAN® Nasal Spray; received U.S. FDA approval of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted).

2023
2025

Obtained commercial rights to KLOXXADO® (naloxone HCI) Nasal Spray 8 mg

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs.

Our Culture and Values

Our culture is informed by our values and commitment to protecting and saving lives. For all the people touched by our work, we operate with an unwavering commitment to honesty, integrity, and quality.

LEARN MORE

Our Leadership

    Joseph Papa

    President and Chief Executive Officer

    Richard S. Lindahl

    Executive Vice President, Chief Financial Officer, and Treasurer

    Coleen Glessner

    Executive Vice President Quality and Ethics and Compliance

    Simon Lowry, M.D.

    Chief Medical Officer, Head of Research and Development

    Paul Williams

    Senior Vice President, Products Business

    Jessica Perl

    Senior Vice President, General Counsel and Corporate Secretary

    Stephanie Duatschek

    Chief Global Strategy & Franchise Development Officer

    Michelle Pepin

    Senior Vice President and Chief Human Resources Officer

    Bill Hartzel

    Senior Vice President, Manufacturing and Bioservices

    Zsolt Harsanyi Ph.D.

    Independent Director, Chairman of the Board

    Joseph Papa

    President and Chief Executive Officer

    Keith Katkin

    Independent Director

    Kathryn C. Zoon Ph.D.

    Independent Director

    Ronald B. Richard

    Independent Director

    Marvin White

    Independent Director

    Sujata Dayal

    Independent Director

    Don DeGolyer

    Independent Director

    Neal Fowler

    Independent Director

    John D. Fowler, Jr.

    Independent Director